Cite
HARVARD Citation
Younes, A. et al. (2019). Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Lancet. 6 (2), pp. e67-e78. [Online].